54 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca.
Silence and AstraZeneca initiated a multi-target collaboration
6-K
EX-99.1
SLN
Silence Therapeutics Plc
14 Nov 23
Current report (foreign)
12:00am
at amortized cost
R&D tax credit receivable
Other current assets
Trade receivables
Non-current liabilities
Contract liabilities
Lease liability
Current … liabilities
Cash spent on operations
Tax paid
R&D tax credits received
Net cash outflow from operating activities
Cash flow from investing activities
Redemption
6-K/A
EX-99.1
SLN
Silence Therapeutics Plc
29 Aug 23
Current report (foreign) (amended)
4:01pm
assets
Financial assets at amortized cost
Current assets
Cash and cash equivalents
Financial assets at amortized cost
R&D tax credit receivable
Other … Receivable
Increase/(Decrease) in trade and other payables
(Decrease) in contract liabilities
Cash spent on operations
R&D tax credits received
Net
6-K
EX-99.1
SLN
Silence Therapeutics Plc
16 Aug 23
Current report (foreign)
7:00am
assets
Financial assets at amortized cost
Current assets
Cash and cash equivalents
Financial assets at amortized cost
R&D tax credit receivable
Other … Receivable
Increase/(Decrease) in trade and other payables
(Decrease) in contract liabilities
Cash spent on operations
R&D tax credits received
Net
S-8
g7vl bb6zj03e98
1 Aug 23
Registration of securities for employees
4:31pm
6-K
EX-99.1
523udbp asfw
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
m3p8rkiuf 69pr
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
uz8k6 4on
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
06827nb d40wxy2
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-99.1
zqlpus4f6gqq gl
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
EX-99.1
yqtn3
16 May 22
Current report (foreign)
8:31am
6-K
EX-99.1
tvmhcysasz
4 Apr 22
Current report (foreign)
8:31am
6-K
EX-99.1
vo42w
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
EX-99.1
2fb gompbj1hztup
16 Nov 21
Current report (foreign)
6:03am
6-K
EX-99.1
r7k6nhk5 kdpunj
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am
6-K
4khwgh4jv2y 9k3
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am
POS AM
3mgwv03y qw7p0ge
18 Oct 21
Prospectus update (post-effective amendment)
5:29pm